Skip to main content
NewslettersWatchlist

Novo Nordisk A/S ADR(NVO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low105.03
Day High108.75
Open:108.27
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

Why this money manager is buying Amazon and Dollarama and recently swapped a cybersecurity stock

Stan Wong of Scotia Wealth Management is an active money manager who invests based on macroeconomic, quantitative and technical analysis
Motley Fool
Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript
Motley Fool
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Barchart
Thanks to Wall Street, Novo Nordisk Stock is Now a Buy
Baystreet
Canada Jobs on Agenda for Next Week
MarketBeat
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Motley Fool
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Motley Fool
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
Motley Fool
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Barchart
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?
Motley Fool
Hims & Hers Stock Dropped: Here's What You Need to Know
Newswire.ca
Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs
MarketBeat
Monster and Celsius Energized: Which Stock Offers More Upside?
MarketBeat
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
The Globe and Mail
Why this money manager sees FirstService, Novo Nordisk and Microsoft as good long-term holdings
GlobeNewswire
Novo Resources Reports 2024 Sustainability Report
Motley Fool
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Motley Fool
3 No-Brainer Growth Stocks to Buy in October
MarketBeat
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Motley Fool
2 No-Brainer Dividend Growth Stocks to Buy Right Now
GlobeNewswire
De Grey Reaches A$7M Minimum Spend at Egina Gold Project and Continues Investment
Motley Fool
Got $5,000? These 3 Growth Stocks Are on Sale Right Now.
MarketBeat
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar

Profile

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.